Upstart Mind Cure (CSE:MCUR) Set To Disrupt $300 Billion Industry
“May revolutionize mental health care” - Fortune
The mental healthcare industry is ripe for innovation.
And companies like Mind Cure (CSE: MCUR)
, which recently completed its IPO, are set to lead the way.
Recently top medical researchers have returned to an old idea to addiction, depression, PTSD, and more.
And, judging by the climb in Mind Cure's shares
, it's working.
Early indications from clinical research say it could, as Fortune Magazine says, “revolutionize mental health care.”1
Top Silicon Valley, venture capital, and biotech investors are getting behind it in a big way.
In the last few months we’ve seen major investments of $30 million2, $80 million3, and a planned $100 million+ later this year.4
Mind Cure CSE:MCUR is positioning itself at being at the front of it all. And with its IPO, it’s poised to take a giant step forward in this race.
The Rise Of Psychedelic-Derived Treatments
In the last few years top medical researchers have rediscovered the positive effects of Psychoactives and the healing power of psychedelics.
Consider a recent article from the Wall Street Journal – the investors paper of record. It reported that this new class of psychedelic-based drugs “can help alleviate depression, anxiety and addiction.”5
Fortune magazine – another seminal source for investors looking to maximize their returns – declared, “Psychedelic drugs may revolutionize mental health care.”6
And NBC News recently proclaimed, “Therapeutic ‘trips’ may someday bring relief from addiction, anxiety, depression — and even the fear of death.”7
And its not just the press either.
Academia is also fully on board. Top researchers at Yale, Johns Hopkins, University of North Carolina,8
and many other top universities worldwide are paving the way forward for an entirely new class of drugs that can change the way we live, how well we live – and how long we live.
The U.S. government has even started researching the remarkable power of psychedelics.
In June of 2020 the Department of Defense’s Defense Advanced Research Projects Agency (DARPA) announced it would invest $26.9 million
into researching medicinal applications for psychedelic drugs.
DARPA said its psychedelics research “aims to create new medications to effectively and rapidly treat depression, anxiety, and substance abuse without major side effects.”9
The rise of psychedelics is here.
There are years of growth ahead and, if psychedelics are as disruptive as some of the world’s top investors believe, there is exponential potential for early investors.
That’s where Mind Cure (CSE:MCUR
) comes in because it’s just starting its growth trajectory.
Mind Cure MCUR Bursts Onto Psychedelic Scene
is a mental health and wellness company focused on identifying, developing and commercializing products that enhance mental health and wellness, ease suffering and increase productivity in the midst of global mental health crisis.10
The company is focusing on the five largest aspects of the psychedelic-derived research market.
has targeted nootropics as a beachhead in the massive global nutritional health industry.
A nootropic is a drug or supplement used to enhance cognitive function and fit right into Mind Cure’s
aggressive growth strategy.
products will be a functional mushroom powder sold under the Moombeam brand. Within the Moonbeam brand there will be targeted products offering specific benefits to consumers with Moonbeam Energy, Focus, and Protection types and we be a quick path to revenues.
has targeted broad range of outlets for distribution throughout the U.S and Canada.
The Company has received its Canadian Health Product Authorization Numbers (HPN) s, which authorizes the sale of natural products like functional mushrooms and will be ramping up sales efforts through multiple channels.
The first physical distribution point is through Body Energy Club franchises. The Body Energy Club has 17 locations in Canada and the United States.
After that, Mind Cure
has announced it will be targeting online sales and distribution directly to consumers and through Amazon, Google Shopping, eBay, Bonanza, and Walmart Marketplace.
The total market for just the functional mushrooms is $23 billion
per year and growing.
will be researching new products that align with and complement its Nootropic Formulations above.
This strategy of research and developing new products allows Mind Cure
to leverage its building customer base and its early-mover advantages in the functional mushroom and broader nootropic sectors.
Clinical Research Technology
Clinical biotech researchers will tell you one of the biggest problems in researching and developing treatments of any kind for mental health is tracking and measurement of the efficacy of the treatment.
has developed user-friendly software to much more actively that targeted at solving that problem.
Formulation and Supply
is currently investigating and developing potential plans including the capital requirements, economics, and timelines for manufacturing, importing, and supplying traditional and novel psychoactive compounds (NPS).
These could include: LSD, NPS’s, MDMA, Ketamine, Psilocybin DMT
may be able to take the information it learns from customer feedback, academic research, and other sources and apply investigate to clinical research for the eventual development and targeting of new product candidates.
In the end, Mind Cure
is a company structured in a way to ride the psychedelics boom in multiple ways.
And the timing of Mind Cure’s
emergence is as good as it gets.
“Mind Cure believes the mental health space is ripe for innovation, and investment that could lead to major disruption in how mental health is treated.”
Mind Cure 2020
Consider Investing In Psychedelics Now
Again, the mental health care industry is long overdue for major innovation.
Anti-depressants, many developed in the middle of the last century, have consistently proven to not be the most effective treatments or even possibly counterproductive in many cases.
Psychedelics have the potential to be the disruptive force that shakes up the entire mental health sector.
And now novel psychedelic treatments have attracted the financial backing of some of the biggest money investors in the world and can truly advance clinical research in psychedelics targeted at the most promising solutions.
That final change – the infusion of capital – will change everything for all facets of the psychedelics industry.
Companies like Mind Cure (MCUR)
may be positioned to ride the psychedelics boom all the way to the top too.
All the best,
Psychedelic Stock Watch Team